Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "World Journal of Hepatology"
DOI: 10.4254/wjh.v14.i6.1248
Abstract: BACKGROUND Hepatitis C virus (HCV) is a leading cause of liver cirrhosis and hepatocellular carcinoma globally. Sofosbuvir/velpatasvir (SOF/VEL) is an effective pan-genotypic direct-acting antiviral combination for treatment of chronic HCV infection. While the addition of… read more here.
Keywords: compensated cirrhosis; sof vel; gt3 compensated; cirrhosis patients ... See more keywords